Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AUTL | PRESS-RELEASE | neutral | 4/10 | Autolus Therapeutics released a post-hoc analysis of the Phase Ib/II FELIX study for ASCO, showing obe-cel achieved a 59 | May 21, 2026 |
| BDTX | PRESS-RELEASE | bullish | 8/10 | Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline NSCLC with EGFR non-classical | May 21, 2026 |
| AKTS | PRESS-RELEASE | bullish | 7/10 | Aktis reported first-in-human clinical imaging and dosimetry data for AKY-2519, a B7-H3-targeted miniprotein radioconjug | May 21, 2026 |
| IMMX | 8-K | bearish | 7/10 | Immix Biopharma priced an underwritten offering of 16,778,524 shares at $8.94 per share, raising $150M in gross proceeds | May 21, 2026 |
| PHVS | 144 | neutral | 3/10 | Director David W. Nassif filed a Form 144 notice of intent to sell 10,000 common shares of Pharvaris N.V., with an estim | May 21, 2026 |
| BDTX | 8-K | bullish | 7/10 | Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline NSCLC patients with EGFR non- | May 21, 2026 |
| MCUJF | 6-K | mixed | 5/10 | Medicure reported Q1 2026 revenue of $7.9M (+45% YoY) driven by pharmacy acquisitions and ZYPITAMAG growth, but net loss | May 21, 2026 |
| ZLAB | 8-K | neutral | 4/10 | Zai Lab's President and COO Josh Smiley is departing effective immediately, with his last day on May 22, 2026. Responsib | May 21, 2026 |
| MCUJF | 6-K | neutral | 3/10 | Medicure Inc. filed a 6-K reporting the results of its Annual General Meeting, where all resolutions passed, including t | May 21, 2026 |
| SNSE | DEFA14A | neutral | 5/10 | Sensei Biotherapeutics filed a DEFA14A proxy supplement providing unaudited pro forma financials for the conversion of S | May 21, 2026 |
| RLAY | 8-K | bearish | 6/10 | Relay Therapeutics entered into an underwriting agreement for a public offering of 22,916,667 shares (plus full over-all | May 21, 2026 |
| OLMA | 8-K | bullish | 6/10 | Olema Pharmaceuticals announced preliminary Phase 1 data for OP-3136, a KAT6 inhibitor, showing acceptable tolerability, | May 21, 2026 |
| BCYC | 8-K | neutral | 5/10 | Bicycle Therapeutics announced initial Phase 2 Duravelo-2 data for zelenectide pevedotin in metastatic urothelial cancer | May 21, 2026 |
| REGN | PRESS-RELEASE | bullish | 6/10 | Regeneron announced positive Phase 1/2 LINKER-AL2 results for Lynozyfic (linvoseltamab) in second-line-plus systemic AL | May 21, 2026 |
| CMPX | PRESS-RELEASE | bullish | 7/10 | Compass Therapeutics announced a poster presentation at ASCO 2026 showing Phase 1 dose-escalation data for CTX-8371, a P | May 21, 2026 |
| OLMA | PRESS-RELEASE | bullish | 6/10 | Olema Oncology announced preliminary Phase 1 data for OP-3136, a KAT6 inhibitor, showing acceptable tolerability and ear | May 21, 2026 |
| LEGN | PRESS-RELEASE | bullish | 7/10 | Legend Biotech announced multiple ASCO 2026 presentations, including a rapid oral presentation of preliminary Phase 1 da | May 21, 2026 |
| CRDF | PRESS-RELEASE | neutral | 4/10 | Cardiff Oncology announced it will present updated Phase 2 data for onvansertib in RAS-mutated mCRC at ASCO on June 2, 2 | May 21, 2026 |
| PTHS | 8-K | bearish | 6/10 | Pelthos Therapeutics filed an 8-K reporting two significant events: (1) the dismissal of auditor CBIZ CPAs P.C. and enga | May 21, 2026 |
| LEGN | 6-K | neutral | 4/10 | Legend Biotech announced it will present preliminary Phase 1 data for LB2102 (DLL3-targeted CAR-T in solid tumors) as a | May 21, 2026 |
| HCWB | 8-K | bearish | 7/10 | HCW Biologics entered into a securities purchase agreement to sell 2,846,975 shares of common stock (or pre-funded warra | May 21, 2026 |
| AZTR | S-1 | bearish | 6/10 | Azitra filed an S-1 registration for the resale of up to 255.7 million shares (526% of outstanding) held by selling stoc | May 21, 2026 |
| ZTS | CLUSTER | neutral | 2/10 | Two Zoetis directors made open-market purchases totaling $653K on May 13, 2026, a modest 0.002% of market cap. Director | May 21, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Insider cluster at United Therapeutics shows CEO and CFO selling small amounts of stock after option exercises, total op | May 21, 2026 |
| BBIO | 144 | neutral | 3/10 | BridgeBio Pharma CEO Neil Kumar filed a Form 144 on May 21, 2026, indicating intent to sell 26,103 shares of common stoc | May 21, 2026 |
| ZLAB | CLUSTER | neutral | 3/10 | Two Zai Lab insiders (CEO and CLO) sold a combined $1.02M in open-market sales, less than 0.05% of market cap. These sal | May 21, 2026 |
| ANIP | 8-K | neutral | 3/10 | ANI Pharmaceuticals held its 2026 Annual Meeting on May 21, 2026, where all seven director nominees were elected, Ernst | May 21, 2026 |
| TLPPF | 6-K | neutral | 2/10 | Telix Pharmaceuticals filed its Annual General Meeting (AGM) materials on May 21, 2026, including Chairman/CEO addresses | May 21, 2026 |
| JSPRW | 8-K | neutral | 2/10 | Jasper Therapeutics disclosed the resignation of board member Christian Nolet, effective May 15, 2026, citing no disagre | May 21, 2026 |
| NGEN | PRESS-RELEASE | bearish | 5/10 | NervGen Pharma announced an underwritten public offering of common shares and warrants (including pre-funded warrants) t | May 21, 2026 |